secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001193125-24-198411
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports 100% AML remission with INB-100; FDA guidance for registrational trial
--------------------------------------------------------------------------------

- 100% of AML patients in Phase 1 trial remain in complete remission; all relapse-free beyond one year.
- Received FDA guidance for registrational trial of INB-100 in AML; IND submission planned Q1 2025.
- INB-200 for GBM shows prolonged survival in higher dose cohorts; one MGMT-unmethylated patient in remission >1 year.
- No new relapses since May 15, 2024; safety manageable with no significant cell therapy-related toxicities.
- INB-400 Phase 2 trial for front-line GBM actively enrolling at multiple US sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524198411/0001193125-24-198411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524198411/d801512d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-198411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer